title: Lamivudine-Associated Pancreatitis: Strongest Evidence to Date.
authors: 1Department of Internal Medicine, SUNY Upstate Medical University Syracuse, NY 2Division of Gastroenterology, Department of Internal Medicine, SUNY Upstate Medical University Syracuse, NY.
authors: Jalaluddin
authors: J
authors: Umar
authors: Adam
authors: A
authors: Zayac
authors: Umair
authors: U
authors: Masood
authors: Sekou
authors: S
authors: Rawlins
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D015224:Dideoxynucleosides / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010078:Oxazines; D010179:Pancreas / Q000000981:diagnostic imaging / Q000187:drug effects; D010195:Pancreatitis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D010879:Piperazines; D011728:Pyridones; D014057:Tomography, X-Ray Computed; D000099227:Abacavir; D000099226:Dolutegravir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D006575:Heterocyclic Compounds, 3-Ring; D019259:Lamivudine; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099227:Abacavir; D000099226:Dolutegravir